Results 191 to 200 of about 7,676,849 (387)

Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension

The Lancet: Digital Health, 2020
Summary: The SPIRIT 2013 statement aims to improve the completeness of clinical trial protocol reporting by providing evidence-based recommendations for the minimum set of items to be addressed.
Samantha Cruz Rivera, PhD, Xiaoxuan Liu, MBChB, An-Wen Chan, MD, Alastair K Denniston, ProfPhD, Melanie J Calvert, ProfPhD, Hutan Ashrafian, Andrew L Beam, Gary S Collins, Ara Darzi, Jonathan J Deeks, M Khair ElZarrad, Cyrus Espinoza, Andre Esteva, Livia Faes, Lavinia Ferrante di Ruffano, John Fletcher, Robert Golub, Hugh Harvey, Charlotte Haug, Christopher Holmes, Adrian Jonas, Pearse A Keane, Christopher J Kelly, Aaron Y Lee, Cecilia S Lee, Elaine Manna, James Matcham, Melissa McCradden, David Moher, Joao Monteiro, Cynthia Mulrow, Luke Oakden-Rayner, Dina Paltoo, Maria Beatrice Panico, Gary Price, Samuel Rowley, Richard Savage, Rupa Sarkar, Sebastian J Vollmer, Christopher Yau   +39 more
doaj  

Patient reported outcome measures could help transform healthcare

British medical journal, 2013
N. Black
semanticscholar   +1 more source

Landscape of BRAF transcript variants in human cancer

Molecular Oncology, EarlyView.
We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda, Danilo Tatoni, Gianluca Mattei, Alberto Magi, Romina D'Aurizio, Laura Poliseno   +5 more
wiley   +1 more source

Patient-reported outcomes 6 months after enhanced recovery after colorectal surgery. [PDF]

, 2018
BackgroundEnhanced recovery after surgery (ERAS) programs have been established as perioperative strategies associated with improved outcomes. However, intermediate and long-term patient-reported outcome data for patients undergoing ERAS interventions ...
Chen, Lee-Lynn, Deiss, Thomas, Naidu, Ramana K, Sarin, Ankit   +3 more
core  

Loss of proton‐sensing GPR4 reduces tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
G protein‐coupled receptor 4 (GPR4) is a pH‐sensing receptor activated by acidic pH. GPR4 expression is increased in patients with inflammatory bowel disease who are at high risk of developing colorectal cancer. In mouse models, loss of GPR4 attenuated tumor progression. This correlated with increased IL2 and natural killer cell activity.
Leonie Perren, Moana Busch, Pedro A. Ruiz, Ermanno Malagola, Valeria Baumeler, Federica Foti, Adelina Gross, Tobias Grütter, Hendrik Edel, Cordelia Schuler, Kristina Handler, Glenn De Lange, Isabelle C. Arnold, Cheryl de Vallière, Klaus Seuwen, Martin Hausmann, Gerhard Rogler   +16 more
wiley   +1 more source

TRPM8 levels determine tumor vulnerability to channel agonists

Molecular Oncology, EarlyView.
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo, Francesco Giuseppe Carbone, Kristi Buzo, Nicole Annesi, Sacha Genovesi, Annalisa Lorenzato, Karen Widmann, Michela Libergoli, Elisa Marmocchi, Giovanni Bertalot, Alberto Brolese, Mauro Giulio Papotti, Luca Molinaro, Orazio Caffo, Mattia Barbareschi, Alberto Bardelli, Alessandro Romanel, Sabrina Arena, Andrea Lunardi   +18 more
wiley   +1 more source

OUTCOME AFTER TRANSPLANTATION OF YOUNG PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A REPORT OF THE NORTH AMERICAN PEDIATRIC RENAL TRANSPLANT COOPERATIVE STUDY

, 2001
Sharon Bartosh, Richard Ν. Fine, E. Kenneth Sullivan   +2 more
openalex   +1 more source

Patient-reported outcome in total hip replacement [PDF]

, 2004
Marieke Ostendorf, Henk F. van Stel, Erik Buskens, A.J.P. Schrijvers, Louis N. Marting, A.J. Verbout, Wouter J.A. Dhert   +6 more
openalex   +1 more source

The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl‐xL or Mcl‐1 in ovarian cancer

Molecular Oncology, EarlyView.
The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect
Cécilia Thomine, Sterenn Guillemot, Louis‐Bastien Weiswald, Romane Florent, Edwige Abeilard, Florence Giffard, Emilie Brotin, Mélanie Briand, Enora Dolivet, Laurent Poulain, Marie Villedieu   +10 more
wiley   +1 more source

DS2: POWER CALCULATIONS FOR WIDELY USED PATIENT-REPORTED OUTCOMES (PRO) MEASURES IN WOMEN'S HEALTH TRIALS

, 2001
Linda Abetz, James Brandman, MARC PLANTE
openalex   +1 more source